Table 3.

Clinical outcomes of the general population.

Clinical outcomes	Total (N = 460)
cACLD at the end of follow-up∗	151 (43)
Progression to cACLD†	34 (10)
Liver decompensation‡	33 (7)
Hepatocellular carcinoma	16 (4)
Death	32 (7)
Non-liver-related§	21 (4–5)
Liver-related	11 (2–4)
Liver transplantation	8 (2)

Qualitative variables are presented as n (%), and quantitative variables are presented as median (IQR). Baseline and follow-up cACLD were assessed only in patients who underwent transient elastography (n = 356).

^∗This group includes patients with cACLD when liver biopsy was performed, plus patients with progression to cACLD from liver biopsy until the end of follow up.

^†Progression to cACLD was defined as new clinical and radiologic criteria for liver cirrhosis or worsening of liver stiffness to ≥15 kPa.

^‡Patients with decompensations at baseline (n = 8) were excluded from this analysis; from n = 452: 29 (6%) ascites, 9 (2%), portal hypertension-related bleeding, 10 (2%) overt encephalopathy, 5 (1%) bacterial spontaneous peritonitis, 4 (1%) portal thrombosis, and 2 (0.4%) hepatorenal syndrome.

^§Non-liver-related death: infectious (10), cardiac (2), neoplastic (2), neurologic (2), and other (5). cACLD, compensated advanced chronic liver disease.